Skip to main content
Clinical Trials/NCT01773083
NCT01773083
Terminated
Phase 3

Randomized Controlled Trial Investigating the Efficacy and Safety of Nebulized Heparin Versus Placebo in Burn Patients With Inhalation Trauma (Hepburn)

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)8 sites in 3 countries13 target enrollmentOctober 2013

Overview

Phase
Phase 3
Intervention
unfractionated heparin
Conditions
Inhalation Injury
Sponsor
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Enrollment
13
Locations
8
Primary Endpoint
Number of ventilator-free days at day 28
Status
Terminated
Last Updated
4 years ago

Overview

Brief Summary

The purpose of this international multi-center double-blind randomized placebo-controlled trial is to determine the effect of nebulized heparin, compared to placebo, on the number of ventilator-free days at day 28, in burn patients with confirmed inhalation trauma requiring mechanical ventilation.

Registry
clinicaltrials.gov
Start Date
October 2013
End Date
December 2017
Last Updated
4 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Prof. Dr. Marcus J. Schultz

Prof. Dr.

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Eligibility Criteria

Inclusion Criteria

  • Informed consent
  • Age \> 18 years
  • Need for invasive mechanical ventilation
  • Confirmed inhalation trauma (bronchoscopically)

Exclusion Criteria

  • \> 36 hours after trauma
  • Receiving invasive ventilation \> 24 hours
  • Expected duration of mechanical ventilation \< 24 hours
  • Chronic obstructive pulmonary disease GOLD stage III and IV
  • Any history of pulmonary hemorrhage in the past 3 months
  • Any history of significant bleeding disorder
  • Known allergy to heparin, including heparin-induced thrombocytopenia
  • Pregnancy or breast feeding
  • Unlikely to survive for \> 72 hours
  • Total body surface area (TBSA) \> 60%

Arms & Interventions

unfractionated heparin

25.000 IU/5 ml, will be nebulized 4 hourly (i.e. 6 times daily)

Intervention: unfractionated heparin

placebo

Sterile sodium chloride (NaCl 0.9%, Pfizer), in 5 ml, will be nebulized every 4 hours (i.e. 6 times daily)

Intervention: placebo

Outcomes

Primary Outcomes

Number of ventilator-free days at day 28

Time Frame: at day 28

The number of ventilator-free days is defined as the number of days a patient is breathing without assist of a ventilator during the first 28 days; thus, the patient must be free of mechanical ventilation for 24 hours to have one ventilator-free day; if after successful detubation the patient requires a reintubation due to a surgical procedure, this reintubation will not count as a ventilator day - however, the day(s) will be counted as ventilator day(s) if mechanical ventilation is prolonged after surgery due to respiratory insufficiency.

Secondary Outcomes

  • Clinical outcome parameters(daily or at day 28 and day 90)
  • Laboratory outcome parameters(Blood and lavage samples: on admission day and every other day for a maximum period of 14 days)
  • Safety parameters(daily, for a maximum period of 28 days)

Study Sites (8)

Loading locations...

Similar Trials